Interleukin-1β influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 35, Issue 3, 2006, Pages 182-188

  Kopp, S ^a   Alstergren, P ^a   Ernestam, S ^b   Nordahl, S ^a   Bratt, J ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; METHOTREXATE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; SIALOGLYCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTHRALGIA; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG EFFECT; DRUG INFUSION; DRUG SYNOVIAL FLUID LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TEMPOROMANDIBULAR JOINT; VENOUS BLOOD; VISUAL ANALOG SCALE; AGED; BLOOD; METABOLISM; MIDDLE AGED; TEMPOROMANDIBULAR JOINT DISORDER;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIALOGLYCOPROTEINS; TEMPOROMANDIBULAR JOINT DISORDERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745121179     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740500483272     Document Type: Article

References (40)

1. Tegelberg A, Kopp S. Clinical findings in the stomatognathic system for individuals with rheumatoid arthritis and osteoarthrosis. Acta Odontol Scand 1987;45:65-75.
2. Helenius LMJ, Hallikainen D, Helenius I, Meurman JH, Koskimies S, Tervahartiala P, et al. HLA-DRB1* alleles and temporomandibular joint erosion in patients with various rheumatic diseases. ScandJRheumatol 2004;33:24-9.
3. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457-99.
4. Niedel J, Schulze M, Lindshau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217-21.
5. Rosengren S, Firestein GS, Boyle DL. Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2003;10:1002-10.
6. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 1994;654:15-26.
7. van de Loo AA, Arntz OJ, Bakker AC, van Lent PL, Jacobs MJ, van den Berg WB. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. AmJPathol 1995;146:239-49.
8. Nordahl S, Alstergren P, Kopp S. Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. JOral Maxillofac Surg 2000;58:525-30.
9. van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Research 2001;3:18-26.
10. Young RE, Thompson RD, Nourshargh S. Divergent mechanisms of action of the inflammatory cytokines interleukin 1-beta and tumour necrosis factor-alpha in mouse cremasteric venules. BrJPharmacol 2002;137:1237-46.
11. Shi J, Schmitt-Talbot E, DiMattia DA, Dullea RG. The differential effects of IL-1 and TNF-alpha on proinflammatory cytokine and matrix metalloproteinase expression in human chondrosarcoma cells. Inflamm Res 2004;53:377-89.
12. Ulfgren AK, Gröndal L, Lindblad S, Khademi M, Johnell O, Klareskog L, et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis 2000;59:439-47.
13. Alstergren P, Ernberg M, Kvarnström M, Kopp S. Interleukin-1β in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility and anterior open bite. JOral Maxillofac Surg 1998;56:1059-65.
14. Nordahl S, Alstergren P, Eliasson S, Kopp S. Interleukin-1β in plasma and synovial fluid in relation to radiographic changes in arthritic temporomandibular joints. EurJOral Sci 1998;106:559-63.
15. Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998;41:1083-9.
16. Alstergren P, Benavente C, Kopp S. Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. JOral Maxillofac Surg 2003;61:1171-8.
17. Voog U, Alstergren P, Eliasson S, Leibur E, Kallikorm R, Kopp S. Progression of radiographic changes in the temporomandibular joints of patients with rheumatoid arthritis in relation to inflammatory markers and mediators in the blood. Acta Odontol Scand 2004;62:7-13.
18. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
19. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. JRheumatol 1999;26:7-15.
20. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
21. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
22. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. NEnglJMed 2000;343:1594-602.
23. Mugnier B, Roudier J. Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 2004;71:91-4.
24. Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J. Reduction of temporomandibular joint pain after infliximab treatment is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis. Cells Tissues Organs 2005;180:22-30.
25. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
26. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.
27. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000;43:2391-6.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
29. Alstergren P, Kopp S, Theodorsson E. Synovial fluid sampling from the temporomandibular joint: sample quality criteria and levels of interleukin-1 beta and serotonin. Acta Odontol Scand 1999;57:16-22.
30. Vey E, Zhang JH, Dayer JM. IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. JImmunol 1992;149:2040-6.
31. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw 1993;4:15-23.
32. Lacraz S, Isler P, Vey E, Welgus HG, Dayer JM. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. JBiol Chem 1994;269:22027-33.
33. Chizzolini C, Chicheportiche R, Burger D, Dayer JM. Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. EurJImmunol 1997;27:171-7.
34. Alstergren P, Ernberg M, Kopp S, Lundeberg T, Theodorsson E. TMJ pain in relation to circulating neuropeptide Y, serotonin, and interleukin-1 beta in rheumatoid arthritis. JOrofac Pain 1999;13:49-55.
35. Kopp S, Alstergren P. Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm 2002;11:211-17.
36. Zeller J, Weissbarth E, Baruth B, Mielke H, Deicher H. Serotonin content of platelets in inflammatory rheumatic diseases: correlation with clinical activity. Arthritis Rheum 1983;26:532-40.
37. Eastgate JA, Symons JA, Wood NC, Capper SJ, Duff GW. Plasma levels of interleukin-1-alpha in rheumatoid arthritis. BrJRheumatol 1991;30:295-7.
38. Gutierrez S, Palacios I, Egido J, Zarco P, Miguelez R, Gonzalez E, et al. IL-1 beta and IL-6 stimulate the production of platelet-activating factor (PAF) by cultured rabbit synovial cells. Clin Exp Immunol 1995;99:364-8.
39. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21.
40. Oberg T, Carlsson GE, Fajers CM. The temporomandibular joint. A morphologic study on a human autopsy material. Acta Odontol Scand 1971;29:349-84.